Background: Dopaminergic system plays an important role in antipsychotic response. Functional single nucleotide polymorphisms (SNPs) can change dopamine receptor expression or dopamine disposition and thus influence response to antipsychotic treatment.
Subjects And Methods: 138 schizophrenia patients were stratified in the treatment-resistant and treatment-responsive group. Control group consisted of 94 healthy blood donors. All subjects were genotyped for the following SNPs: DRD1 (rs4532, rs5326), DRD2 (rs1801028, rs1799732), DRD3 (rs6280) and COMT (rs165815, rs4680). Association between the genotypes and clinical symptoms were tested using ANCOVA with current antipsychotic dose as a confounder. Differences in allele frequencies between treatment-responsive and treatment-resistant schizophrenic patients were assessed using χ(2) tests.
Results: No statistically significant associations were observed between any of the investigated genotypes and clinical scores and occurrence of the treatment-resistant schizophrenia.
Conclusions: Genetic variability in dopaminergic system does not have a major role in clinical symptoms and occurrence of treatment-resistant schizophrenia among Slovenian patients.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
MRI-guided focused ultrasound for treating Parkinson's disease with human mesenchymal stem cells.
Sci Rep
January 2025
Physical Sciences Platform, Sunnybrook Research Institute, Toronto, ON, Canada.
Parkinson's disease (PD) is a progressive disorder that affects the nervous system and causes regions of the brain to deteriorate. In this study, we investigated the effects of MR-guided focused ultrasound (MRgFUS) for the delivery of human mesenchymal stem cells (MSCs) on the 6-hydroxydopamine (6-HODA)-induced PD rat model. MRgFUS-induced blood-brain barrier (BBB) permeability modulation was conducted using an acoustic controller with the targets at the striatum (ST) and SN.
View Article and Find Full Text PDFChoroidal thickening and retinal dopamine increase in mice at high altitude.
Exp Eye Res
January 2025
Department of Ophthalmology, The Second Hospital &Clinical Medical School, Lanzhou University, Gansu 730000, China. Electronic address:
The mechanisms underlying the low incidence of myopia at high altitudes remain unclear. Choroidal thickness and the dopaminergic system have been shown to be closely associated with myopia development. This study aimed to investigate the effects of high altitude exposure on choroidal thickness and the dopaminergic system.
View Article and Find Full Text PDFA nanoparticle-based wireless deep brain stimulation system that reverses Parkinson's disease.
Sci Adv
January 2025
New Cornerstone Science Laboratory, CAS Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety & CAS Center for Excellence in Nanoscience, National Center for Nanoscience and Technology of China, Beijing 100190, China.
Deep brain stimulation technology enables the neural modulation with precise spatial control but requires permanent implantation of conduits. Here, we describe a photothermal wireless deep brain stimulation nanosystem capable of eliminating α-synuclein aggregates and restoring degenerated dopamine neurons in the substantia nigra to treat Parkinson's disease. This nanosystem (ATB NPs) consists of gold nanoshell, an antibody against the heat-sensitive transient receptor potential vanilloid family member 1 (TRPV1), and β-synuclein (β-syn) peptides with a near infrared-responsive linker.
View Article and Find Full Text PDFCannabinoid-based Pharmacology for the Management of Substance Use Disorders.
Curr Top Behav Neurosci
January 2025
Department of Neurobiology, University of Maryland, School of Medicine, Baltimore, MD, USA.
In the last two decades, the endocannabinoid system has emerged as a crucial modulator of motivation and emotional processing. Due to its widespread neuroanatomical distribution and characteristic retrograde signaling nature, cannabinoid type I receptors and their endogenous ligands finely orchestrate somatic and axon terminal activity of dopamine neurons. Owing to these unique features, this signaling system is a promising pharmacological target to ameliorate dopamine-mediated drug-seeking behaviors while circumventing the adverse side effects of, for instance, dopaminergic antagonists.
View Article and Find Full Text PDFImpulse control disorders in Parkinson's disease: What's new?
J Neurol
January 2025
Parkinson's Disease Research Clinic, Macquarie University, 75 Talavera Road, Sydney, NSW, 2109, Australia.
Impulse Control Disorders (ICDs) are increasingly recognized as a significant non-motor complication in Parkinson's disease (PD), impacting patients and their caregivers. ICDs in PD are primarily associated with dopaminergic treatments, particularly dopamine agonists, though not all patients develop these disorders, indicating a role for genetic and other clinical factors. Studies over the past few years suggest that the mesocorticolimbic reward system, a core neural substrate for impulsivity, is a key contributor to ICDs in PD.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!